[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566744":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":10,"responsibleParty":26,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":32,"sex":38,"minAge":39,"maxAge":10,"enrollmentInfo":40,"targetDuration":10,"studyType":43,"phases":10,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":10},{"fullName":5,"class":6},"Klinik Hirslanden, Zurich","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GLP-1, New Therapy",null,"Indication, prescription and dosage is determined independently of the study by the endocrinologist\u002Fobesity specialist, who is also part of the study team. Since the first gastric ultrasound will take place directly before the initiation of the GLP-1 Agonist therapy, the patients will serve as their own control group\u002Fbaseline.",[13],"Diagnostic Test: Gastric ultrasound",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Gastric ultrasound","The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality\u002Fquantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).\n\nIn accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Michael Ganter Director and Chairman Institute of Anesthesiology and Intensiv, Prof. Dr. med.","CONTACT","+41 44 387 38 80","Michael.Ganter@hirslanden.ch",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Sascha Battig","Prof. Dr. med. Michael Ganter","100566744","effects-of-beginning-a-glp1-agonist-therapy-on-residual-gastric-content-and-gastric-emptying-100566744",false,"NCT06659159","Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying","Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying: a Prospective Ultrasound Approach with Focus on Perioperative Aspiration Risk.","GLP-1","Inclusion Criteria:\n\n* Beginning a new treatment with GLP-1 Agonists. Indication and prescription determined by an endocrinologist\u002Fobesity specialist\n* Signed informed consent\n\nExclusion Criteria:\n\n* Known pregnancy, known lactation\n* Underage (\\\u003C 18 years)\n* Absence of informed consent (missing or inability to provide)\n* Anomalies of the gastrointestinal tract\n* Known illnesses of the gastrointestinal tract\n* Previous surgery of the gastrointestinal tract\n* Elevated risk for hypoglycaemia (Sulfonylurea or Insulin)\n* No investigator with completed structural education in gastric sonography is available\n* Lack of intention to respect the fasting intervals and predefined standardised meals for the sonographic examination","ALL","18 Years",{"count":41,"type":42},50,"ESTIMATED","OBSERVATIONAL","This project explores the elevated risk of pulmonary aspiration during anesthesia in patients undergoing GLP-1 agonist therapy, which prolongs gastric emptying. Despite standard fasting guidelines (6 hours for solids, 2 hours for liquids), some patients still experience aspiration, indicating that GLP-1 therapy may heighten risk. The American Society of Anesthesiologists has advised pausing GLP-1 therapy before surgery, but this recommendation has faced criticism for being too broad. More data on this issue is needed, particularly concerning the effect of tachyphylaxis (reduced drug response over time) on gastric emptying.\n\nThe study proposes using gastric ultrasound as a non-invasive tool to evaluate residual gastric content and categorize patients by their aspiration risk. The study will assess the stomach's content and gastric emptying time in patients both before and after starting GLP-1 therapy, comparing results under standard fasting conditions.\n\nThe project is a national, single-center, prospective observational study targeting 50 patients, examining factors like patient demographics, GLP-1 therapy details, and gastrointestinal side effects. Data collection will occur through baseline and follow-up sonographic exams before and after therapy initiation. The study aims to improve perioperative management strategies by clarifying the risks associated with GLP-1 therapy",[46],"Pulmonary Aspiration During Anaesthetic Induction",[48,17,36,49],"Pulmonary aspiration","Gastroparesis","NOT_YET_RECRUITING","2024-10-23",{"date":53,"type":54},"2024-10-26","ACTUAL",{"date":56,"type":42},"2024-11-01",{"date":58,"type":42},"2026-12-31",{"name":28,"class":6}]